? New research raises serious questions about whether remediated cannabis products are truly safe from mold contamination, even after passing state-mandated testing. The concern is that current lab protocols do not screen for the specific fungal species most likely to cause illness, particularly in immunocompromised patients and those with respiratory vulnerability. Perhaps most alarming is evidence suggesting that vaporization temperatures are insufficient to neutralize these organisms, undermining a safety assumption many clinicians and patients have relied on. The potential connection between residual mold contaminants and cannabis hyperemesis syndrome adds another layer of clinical urgency. ️ Until testing standards catch up with the science, clinicians should be counseling at-risk patients about these limitations and considering product sourcing as part of the clinical conversation.